{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:39:17Z","timestamp":1791639557995,"version":"4.3.4"},"reference-count":101,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,2,2]],"date-time":"2020-02-02T00:00:00Z","timestamp":1580601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key R&amp;D Program of China","award":["2017YFD0500400"],"award-info":[{"award-number":["2017YFD0500400"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572012"],"award-info":[{"award-number":["81572012"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772217"],"award-info":[{"award-number":["81772217"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["20180907"],"award-info":[{"award-number":["20180907"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971954"],"award-info":[{"award-number":["81971954"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangdong Provincial Natural Science Foundation Project","award":["2016A030311025"],"award-info":[{"award-number":["2016A030311025"]}]},{"name":"Guangdong Provincial Natural Science Foundation Project","award":["2017A03031369"],"award-info":[{"award-number":["2017A03031369"]}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["2018A050506038"],"award-info":[{"award-number":["2018A050506038"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key project of Guangzhou science research","award":["201904020011"],"award-info":[{"award-number":["201904020011"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Dengue virus (DENV) has become a global health threat with about half of the world\u2019s population at risk of infection. Although the disease caused by DENV is self-limiting in the first infection, the antibody-dependent enhancement (ADE) effect increases the mortality in the second infection with a heterotypic virus. Since there is no specific efficient medicine in treatment, it is urgent to develop vaccines to prevent infection and disease progression. Currently, only a live attenuated vaccine, chimeric yellow fever 17D\u2014tetravalent dengue vaccine (CYD-TDV), has been licensed for clinical use in some countries, and many candidate vaccines are still under research and development. This review discusses the progress, strengths, and weaknesses of the five types of vaccines including live attenuated vaccine, inactivated virus vaccine, recombinant subunit vaccine, viral vectored vaccine, and DNA vaccine.<\/jats:p>","DOI":"10.3390\/vaccines8010063","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T11:28:31Z","timestamp":1580729311000},"page":"63","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":146,"title":["A Review on Dengue Vaccine Development"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0901-7661","authenticated-orcid":false,"given":"Sheng-Qun","family":"Deng","sequence":"first","affiliation":[{"name":"Department of Pathogen Biology, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pathogen Biology, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pathogen Biology, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ting","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathogen Biology, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Guangdong Medical University, Dongguan 523808, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9345-8218","authenticated-orcid":false,"given":"Hong-Juan","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Pathogen Biology, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"11418","DOI":"10.1128\/JVI.01257-06","article-title":"Recent Advances in Deciphering Viral and Host Determinants of Dengue Virus Replication and Pathogenesis","volume":"80","author":"Clyde","year":"2006","journal-title":"J. Virol."},{"key":"ref_2","unstructured":"(2019, September 24). Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control: New Edition, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK143157\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.biotechadv.2010.11.008","article-title":"Review of dengue virus and the development of a vaccine","volume":"29","author":"Murrell","year":"2011","journal-title":"Biotechnol. Adv."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1126\/science.131.3407.1102","article-title":"Viruses Associated with Epidemic Hemorrhagic Fevers of the Philippines and Thailand","volume":"131","author":"Hammon","year":"1960","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.antiviral.2012.09.018","article-title":"Neutralization of dengue virus in the presence of Fc receptor-mediated phagocytosis distinguishes serotype-specific from cross-neutralizing antibodies","volume":"96","author":"Wu","year":"2012","journal-title":"Antivir. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.virol.2009.09.024","article-title":"Dengue virus neutralization is modulated by igg antibody subclass and fc\u03b3 receptor subtype","volume":"394","author":"Rodrigo","year":"2009","journal-title":"Virology"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Montoya, M., Gresh, L., Mercado, J.C., Williams, K.L., Vargas, M.J., Gutierrez, G., Kuan, G., Gordon, A., Balmaseda, A., and Harris, E. (2013). Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Neglect. Trop. Dis., 7.","DOI":"10.1371\/journal.pntd.0002357"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"20130414","DOI":"10.1098\/rsif.2013.0414","article-title":"Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity","volume":"10","author":"Reich","year":"2013","journal-title":"J. R. Soc. Interface"},{"key":"ref_9","first-page":"1","article-title":"Prospective Cohort Studies of Dengue Viral Transmission and Severity of Disease","volume":"338","author":"Endy","year":"2010","journal-title":"Curr. Top. Microbiol."},{"key":"ref_10","unstructured":"(2019, September 24). Global Strategy for dengue prevention and control, 2012\u20132020. Available online: https:\/\/www.who.int\/denguecontrol\/9789241504034\/en\/."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/B978-0-12-800098-4.00007-6","article-title":"Dengue virus vaccine development","volume":"88","author":"Yauch","year":"2014","journal-title":"Adv. Virus Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1038\/emi.2016.74","article-title":"Vaccines and immunization strategies for dengue prevention","volume":"5","author":"Liu","year":"2016","journal-title":"Emerg. Microbes Infec."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/cmi.2015.76","article-title":"Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine","volume":"13","author":"Liang","year":"2016","journal-title":"Cell Mol. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1126\/scitranslmed.aaa3863","article-title":"Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity","volume":"7","author":"Modhiran","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ritchie, S.A., Pyke, A.T., Sonja, H.M., Andrew, D., Mores, C.N., Christofferson, R.C., Gubler, D.J., Bennett, S.N., and Hurk, A.F. (2013). An explosive epidemic of denv-3 in cairns, australia. PLoS ONE, 8.","DOI":"10.1371\/annotation\/a8dfd4ee-f4b7-443e-bf78-ebb0dab4e55b"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4269\/ajtmh.2006.75.1113","article-title":"Dengue hemorrhagic fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001\u20132002","volume":"75","author":"Alvarez","year":"2006","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.3277268","article-title":"Pathogenesis of dengue: Challenges to molecular biology","volume":"239","author":"Halstead","year":"1988","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.antiviral.2008.06.010","article-title":"Mouse models of dengue virus infection and disease","volume":"80","author":"Yauch","year":"2008","journal-title":"Antiviral Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3389\/fimmu.2014.00452","article-title":"Utility, Limitations, and Future of Non-Human Primates for Dengue Research and Vaccine Development","volume":"5","author":"Sariol","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nrmicro1690","article-title":"Prospects for a dengue virus vaccine","volume":"5","author":"Whitehead","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.enzmictec.2012.05.005","article-title":"Using recombinant DNA technology for the development of live-attenuated dengue vaccines","volume":"51","author":"Lee","year":"2012","journal-title":"Enzyme Microb. Technol."},{"key":"ref_22","unstructured":"(2019, September 24). WHO expert committee on biological standardization. Available online: https:\/\/www.who.int\/biologicals\/expert_committee\/en\/."},{"key":"ref_23","first-page":"1","article-title":"A recombinant live attenuated tetravalent vaccine for the prevention of dengue","volume":"7","author":"Guy","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","article-title":"Preclinical and clinical development of yfv 17d-based chimeric vaccines against dengue, west nile and japanese encephalitis viruses","volume":"28","author":"Guy","year":"2010","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1586\/14760584.2016.1115727","article-title":"Development of TV003\/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD vaccine?","volume":"15","author":"Whitehead","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1016\/j.vaccine.2015.05.059","article-title":"Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia","volume":"33","author":"Dorigatti","year":"2015","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"World Health Organization (2019). Background paper on dengue vaccines. Vaccine, 37, 4848\u20134849.","DOI":"10.1016\/j.vaccine.2018.09.063"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7051","DOI":"10.1016\/j.vaccine.2015.09.112","article-title":"Mouse models of dengue virus infection for vaccine testing","volume":"33","author":"Sarathy","year":"2015","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e830","DOI":"10.1016\/S2214-109X(18)30295-X","article-title":"Dengue vaccine: Reliably determining previous exposure","volume":"6","year":"2018","journal-title":"Lancet Glob. Health"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7242","DOI":"10.1016\/j.vaccine.2011.07.023","article-title":"Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine","volume":"29","author":"Durbin","year":"2011","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1073\/pnas.88.12.5139","article-title":"Infectious rna transcribed from stably cloned full-length cdna of dengue type 4 virus","volume":"88","author":"Lai","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4269\/ajtmh.2008.78.426","article-title":"Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children","volume":"78","author":"Simasathien","year":"2008","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.inf.0000109289.55856.27","article-title":"Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children","volume":"23","author":"Sabchareon","year":"2004","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1128\/jvi.70.6.3930-3937.1996","article-title":"Dengue type 4 virus mutants containing deletions in the 3\u2019 noncoding region of the RNA genome: Analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys","volume":"70","author":"Men","year":"1996","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4269\/ajtmh.2001.65.405","article-title":"Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3\u2019-untranslated region","volume":"65","author":"Durbin","year":"2001","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4269\/ajtmh.2001.65.414","article-title":"A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes","volume":"65","author":"Troyer","year":"2001","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9731","DOI":"10.1128\/JVI.75.20.9731-9740.2001","article-title":"Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice","volume":"75","author":"Blaney","year":"2001","journal-title":"J. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1128\/JVI.76.2.525-531.2002","article-title":"Paired charge-to-alanine mutagenesis of dengue virus type 4 ns5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes","volume":"76","author":"Hanley","year":"2001","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1016\/j.vaccine.2004.02.031","article-title":"Introduction of mutations into the non-structural genes or 3\u2019 untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity","volume":"22","author":"Hanley","year":"2004","journal-title":"Vaccine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1128\/JVI.77.2.1653-1657.2003","article-title":"A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3\u2019 untranslated region is highly attenuated and immunogenic in monkeys","volume":"77","author":"Stephen","year":"2003","journal-title":"J. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/infdis\/jis936","article-title":"A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: A randomized, double-blind clinical trial","volume":"207","author":"Durbin","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/infdis\/jiv082","article-title":"Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults","volume":"212","author":"Kirkpatrick","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"Kirkpatrick","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2011.11.072","article-title":"Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice","volume":"30","author":"Brewoo","year":"2012","journal-title":"Vaccine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/infdis\/174.6.1176","article-title":"Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: Immunogenicity and protection in mice and rhesus monkeys","volume":"174","author":"Putnak","year":"1996","journal-title":"J. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"504","DOI":"10.4269\/ajtmh.1996.55.504","article-title":"Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells","volume":"55","author":"Putnak","year":"1996","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1016\/j.vaccine.2005.03.042","article-title":"An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model","volume":"23","author":"Robert","year":"2005","journal-title":"Vaccine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.virol.2009.10.023","article-title":"Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy","volume":"396","author":"Simmons","year":"2010","journal-title":"Virology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1086\/503372","article-title":"Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination","volume":"193","author":"Sun","year":"2006","journal-title":"Infect. Dis-nor."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.3389\/fimmu.2018.01919","article-title":"Recent Developments in Recombinant Protein-Based Dengue Vaccines","volume":"9","author":"Tripathi","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.apjtm.2017.03.003","article-title":"Towards development of a universal dengue vaccine\u2014How close are we?","volume":"10","author":"Pang","year":"2017","journal-title":"Asian Pac. J. Trop. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.3389\/fmicb.2017.02644","article-title":"Pichia pastoris-expressed bivalent virus-like particulate vaccine induces domain iii-focused bivalent neutralizing antibodies without antibody-dependent enhancement in vivo","volume":"8","author":"Rahul","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10295-013-1235-0","article-title":"Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells","volume":"40","author":"Berlec","year":"2013","journal-title":"J. Ind. Microbiol. Biot."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1016\/j.vaccine.2008.07.006","article-title":"Immunogenicity of a recombinant envelope domain iii protein of dengue virus type-4 with various adjuvants in mice","volume":"26","author":"Babu","year":"2008","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1139\/w11-137","article-title":"Eliciting cross-neutralizing antibodies in mice challenged with a dengue virus envelope domain iii expressed in escherichia coli","volume":"58","author":"Yang","year":"2012","journal-title":"Can. J. Microbiol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"60 Chiang, C.Y., Hsieh, C.H., Chen, M.Y., Tsai, J.P., Liu, H.H., Liu, S.J., Chong, P., Leng, C.H., and Chen, H.W. (2014). Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity. Vaccine, 32, 1346\u20131353.","DOI":"10.1016\/j.vaccine.2014.01.041"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00705-013-1639-1","article-title":"A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates","volume":"158","author":"Chen","year":"2013","journal-title":"Arch. Virol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.vaccine.2016.01.009","article-title":"Recombinant lipidated dengue-3 envelope protein domain III stimulates broad immune responses in mice","volume":"34","author":"Chiang","year":"2016","journal-title":"Vaccine"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"30648","DOI":"10.1038\/srep30648","article-title":"Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice","volume":"6","author":"Chiang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1042\/BA20080074","article-title":"Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice","volume":"52","author":"Lazo","year":"2011","journal-title":"Biotechnol. Appl. Bioc."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/1348-0421.12140","article-title":"Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus","volume":"58","author":"Lazo","year":"2014","journal-title":"Microbiol. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Zhao, H., Jiang, T., Zhou, X.Z., Deng, Y.Q., Li, X.F., Chen, S.P., Zhu, S.Y., Zhou, X., Qin, E.D., and Qin, C.F. (2014). Induction of Neutralizing Antibodies against Four Serotypes of Dengue Viruses by MixBiEDIII, a Tetravalent Dengue Vaccine. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086573"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12934-018-0876-0","article-title":"Comparative immunogenicity of preparations of yeast-derived dengue oral vaccine candidate","volume":"17","author":"Bal","year":"2018","journal-title":"Microb. Cell Fact."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.vaccine.2010.01.022","article-title":"Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys","volume":"28","author":"Clements","year":"2010","journal-title":"Vaccine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1016\/j.vaccine.2015.06.067","article-title":"Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates","volume":"33","author":"Govindarajan","year":"2015","journal-title":"Vaccine"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/j.trivac.2013.10.001","article-title":"Analysis of recombinant, multivalent dengue virus containing envelope (E) proteins from serotypes-1, -3 and -4 and expressed in baculovirus","volume":"4","author":"Rantam","year":"2015","journal-title":"Trials Vaccinol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6308","DOI":"10.1016\/j.vaccine.2017.09.063","article-title":"Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequence","volume":"35","author":"Sun","year":"2017","journal-title":"Vaccine"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/pbi.12741","article-title":"Molecular engineering and plant expression of an immunoglobulin heavy chain scaffold for delivery of a dengue vaccine candidate","volume":"15","author":"Kim","year":"2017","journal-title":"Plant Biotechnol. J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12257-009-3011-6","article-title":"Expression of dengue virus e glycoprotein domain iii in non-nicotine transgenic tobacco plants","volume":"14","author":"Kim","year":"2009","journal-title":"Biotechnol. Bioproc. Eng."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11240-018-01544-9","article-title":"Evaluation of the oral immunogenicity of M cell-targeted tetravalent EDIII antigen for development of plant-based edible vaccine against dengue infection","volume":"137","author":"Kim","year":"2019","journal-title":"Plant Cell Tiss. Org."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1128\/jvi.61.12.4019-4022.1987","article-title":"Expression of dengue virus structural proteins and nonstructural protein NS1 by a recombinant vaccinia virus","volume":"61","author":"Zhao","year":"1987","journal-title":"J. Virol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1128\/jvi.65.3.1400-1407.1991","article-title":"Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice","volume":"65","author":"Men","year":"1991","journal-title":"J. Virol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1128\/jvi.63.6.2853-2856.1989","article-title":"Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein ns1 are protected against fatal dengue virus encephalitis","volume":"63","author":"Bray","year":"1989","journal-title":"J. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1128\/jvi.62.8.3027-3031.1988","article-title":"Immunization of mice with dengue structural proteins and nonstructural protein NS1 expressed by baculovirus recombinant induces resistance to dengue virus encephalitis","volume":"62","author":"Zhang","year":"1988","journal-title":"J. Virol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1016\/S0264-410X(00)00121-3","article-title":"Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge","volume":"18","author":"Men","year":"2000","journal-title":"Vaccine"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jama.289.5.622-a","article-title":"Genetics:molecular therapy: The journal of the american society of gene therapy","volume":"289","author":"Andrea","year":"2003","journal-title":"Jama-J. Am. Med. Assoc."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"12907","DOI":"10.1128\/JVI.77.23.12907-12913.2003","article-title":"Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2","volume":"77","author":"Smita","year":"2003","journal-title":"J. Virol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Khanam, S., Rajendra, P., Khanna, N., and Swaminathan, S. (2007). An adenovirus prime\/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes. BMC Biotechnol., 7.","DOI":"10.1186\/1472-6750-7-10"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1016\/j.vaccine.2009.07.073","article-title":"An adenovirus type 5 (adv5) vector encoding an envelope domain iii-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior adv5 immunity","volume":"27","author":"Khanam","year":"2009","journal-title":"Vaccine"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1128\/CVI.00330-06","article-title":"Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes","volume":"14","author":"Holman","year":"2007","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"6927","DOI":"10.1128\/JVI.02724-07","article-title":"A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue Virus","volume":"82","author":"Raviprakash","year":"2008","journal-title":"J. Virol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1128\/JVI.74.2.914-922.2000","article-title":"Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis","volume":"74","author":"Macdonald","year":"2000","journal-title":"J. Virol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1073\/pnas.0600287103","article-title":"Mucosal and systemic adjuvant activity of alphavirus replicon particles","volume":"103","author":"Thompson","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"11634","DOI":"10.1128\/JVI.00996-07","article-title":"A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques","volume":"81","author":"Chen","year":"2007","journal-title":"J. Virol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1128\/JVI.02298-12","article-title":"An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection","volume":"87","author":"White","year":"2013","journal-title":"J. Virol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1016\/j.vaccine.2014.05.053","article-title":"A tetravalent alphavirus-vector based dengue vaccine provides effective immunity in an early life mouse model","volume":"32","author":"Khalil","year":"2014","journal-title":"Vaccine"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0264-410X(97)00215-6","article-title":"Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice","volume":"15","author":"Kochel","year":"1997","journal-title":"Vaccine"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/S0264-410X(99)00570-8","article-title":"Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein","volume":"18","author":"Raviprakash","year":"2000","journal-title":"Vaccine"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1016\/S0264-410X(00)00105-5","article-title":"A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys","volume":"18","author":"Kochel","year":"2000","journal-title":"Vaccine"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.vaccine.2010.11.050","article-title":"Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial","volume":"29","author":"Beckett","year":"2011","journal-title":"Vaccine"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s007050050348","article-title":"Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses","volume":"143","author":"Porter","year":"1998","journal-title":"Arch. Virol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"420","DOI":"10.4269\/ajtmh.2001.65.420","article-title":"Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine","volume":"65","author":"Simmons","year":"2001","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"9577","DOI":"10.1128\/JVI.00284-06","article-title":"Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques","volume":"80","author":"Simmons","year":"2006","journal-title":"J. Virol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1006\/viro.2001.1136","article-title":"Synergistic Neutralizing Antibody Response to a Dengue Virus Type 2 DNA Vaccine by Incorporation of Lysosome-Associated Membrane Protein Sequences and Use of Plasmid Expressing GM-CSF","volume":"290","author":"Raviprakash","year":"2001","journal-title":"Virology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fimmu.2019.00059","article-title":"Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4(+) T Cells to the Dengue Virus Envelope Protein Domain III","volume":"10","author":"Zaneti","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4269\/ajtmh.17-0416","article-title":"Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial","volume":"98","author":"Danko","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1016\/j.vaccine.2011.07.019","article-title":"Development of dengue dna vaccines","volume":"29","author":"Danko","year":"2011","journal-title":"Vaccine"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/1\/63\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:53:54Z","timestamp":1760172834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/1\/63"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,2]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["vaccines8010063"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8010063","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,2]]}}}